Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
30Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $41.0K | $-88.09M | $-1.00 |
| 2024 | $20.0K | $-95.06M | $-1.34 |
| 2023 | $426.0K | $-88.45M | $-1.66 |
| 2022 | $-68.0K | $-84.71M | $-1.81 |
| 2021 | $4.41M | $-97.09M | $-2.35 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.14 per share
Typical surprise +15.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.12 vs $-0.14beat
- Wed, May 13$-0.18 vs $-0.25beat
- Thu, Mar 5$-0.27 vs $-0.25miss
- Thu, Nov 6$-0.21 vs $-0.29beat
- Tue, Aug 12$-0.27 vs $-0.32beat
- Tue, May 13$-0.26 vs $-0.35beat
Estimates and results for ALT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ALThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (4)
- Newszacks.com·2d ago·Negative
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·3d ago·Neutral
Altimmune Q2 Earnings Call Highlights Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Altimmune Announces Second Quarter 2026 Financial Results and Business Update Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.
View source ↗